» Articles » PMID: 25494640

Clinical and Microbiological Characteristics of Bloodstream Infections Due to AmpC β-lactamase Producing Enterobacteriaceae: an Active Surveillance Cohort in a Large Centralized Canadian Region

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2014 Dec 16
PMID 25494640
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The objective of this study was to describe the clinical and microbiological characteristics of bloodstream infections (BSIs) due to AmpC producing Enterobacteriaceae (AE) in a large centralized Canadian region over a 9-year period.

Methods: An active surveillance cohort design in Calgary, Canada.

Results: A cohort of 458 episodes of BSIs caused by AE was assembled for analysis. The majority of infections were of nosocomial origin with unknown sources. Enterobacter spp. was the most common species while BSIs due to Serratia spp. had a significant higher mortality when compared to other AE. Delays in empiric or definitive antibiotic therapy were not associated with a difference in outcome. However, patients that did not receive any empiric antimicrobial therapy had increased mortality (3/5; 60% vs. 57/453; 13%; p = 0.018) as did those that did not receive definitive therapy (6/17; 35% vs. 54/441; 12%; p = 0.015).

Conclusions: Delays in therapy were not associated with adverse outcomes although lack of active therapy was associated with increased mortality. A strategy for BSIs due to AE where β-lactam antibiotics (including oxyimino-cephalosporins) are used initially followed by a switch to non-β-lactam antibiotics once susceptibility results are available is effective.

Citing Articles

Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis.

Onorato L, De Luca I, Salvati A, Monari C, Coppola N Infection. 2024; .

PMID: 39630396 DOI: 10.1007/s15010-024-02447-y.


Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales.

Tebano G, Zaghi I, Cricca M, Cristini F Pharmacy (Basel). 2024; 12(5).

PMID: 39311133 PMC: 11417830. DOI: 10.3390/pharmacy12050142.


Mortality and Risk Factors of Death in Patients with AmpC -Lactamase Producing Bloodstream Infection: A .

Silva A, Silva N, do Valle F, da Rocha J, Ehrlich S, Martins I Infect Drug Resist. 2024; 17:4023-4035.

PMID: 39309068 PMC: 11416777. DOI: 10.2147/IDR.S473789.


Clinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study.

Shalabi O, Kashat L, Murik O, Zevin S, Assous M, Ben-Chetrit E Antibiotics (Basel). 2024; 13(8).

PMID: 39200009 PMC: 11350690. DOI: 10.3390/antibiotics13080709.


Burden and Management of Multi-Drug Resistant Organism Infections in Solid Organ Transplant Recipients Across the World: A Narrative Review.

Freire M, Pouch S, Manesh A, Giannella M Transpl Int. 2024; 37:12469.

PMID: 38952482 PMC: 11215024. DOI: 10.3389/ti.2024.12469.


References
1.
Goldstein F . Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect. 2003; 8(12):823-5. DOI: 10.1046/j.1469-0691.2002.00492.x. View

2.
Choi S, Kim Y, Chung J, Kim T, Choo E, Kim M . Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol. 2003; 23(12):740-7. DOI: 10.1086/502004. View

3.
Lodise T, McKinnon P, Swiderski L, Rybak M . Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003; 36(11):1418-23. DOI: 10.1086/375057. View

4.
Kim B, Lee S, Choi S, Kim N, Woo J, Ryu J . Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents. 2003; 22(2):106-11. DOI: 10.1016/s0924-8579(03)00094-3. View

5.
Livermore D, Brown D, Quinn J, Carmeli Y, Paterson D, Yu V . Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. Clin Microbiol Infect. 2004; 10(1):84-5. DOI: 10.1111/j.1469-0691.2004.00831.x. View